Credit: Virginia Tech
In an invited review article this week in Cancer Discovery, a journal of the American Association for Cancer Research, Kathleen Mulvaney, a Virginia Tech assistant professor with the Fralin Biomedical Research Institute at VTC, talks about the potential of a new drug that has shown early promise in clinical trials for solid tumors by killing cancer cells that lack specific genes.